Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Valeant Pharmaceuticals International Inc (NYSE:VRX)

16.35
Delayed Data
As of Feb 22
 -0.05 / -0.30%
Today’s Change
13.00
Today|||52-Week Range
86.55
+12.60%
Year-to-Date
Silver Point Capital L.P. Buys Basic Energy Services, Key Energy Services, Penn Virgi...
Feb 22 / GuruFocus News - Paid Partner Content
Valeant's (VRX) Plaque Psoriasis Drug Approved in the U.S.
Feb 17 / Zacks.com - Paid Partner Content
Valeant Acquires Eyegate Licensing Rights
Feb 21 / TheStreet.com - Paid Partner Content
It Happened Again! Another Drugmaker Got Caught With an Exorbitant Price Hike
Feb 17 / MotleyFool.com - Paid Partner Content
The Zacks Analyst Blog Highlights: Merck, Valeant Pharmaceuticals International, Alle...
Feb 21 / Zacks.com - Paid Partner Content
AstraZeneca Stock Rises On Successful Breast Cancer Drug Trial
Feb 17 / TheStreet.com - Paid Partner Content
This Guru Loves Valeant; Should You?
Feb 20 / GuruFocus News - Paid Partner Content
Pharma Stock Roundup: Merck's Alzheimer's Study Halted, Allergan to Buy ZELTIQ
Feb 17 / Zacks.com - Paid Partner Content
European Benchmarks Fall, But London Bucks Trend on Takeover Activity
Feb 17 / TheStreet.com - Paid Partner Content
Don't Count on Valeant's New Drug to Save the Day
Feb 16 / MotleyFool.com - Paid Partner Content

Today’s Trading

Previous close16.40
Today’s open16.34
Day’s range16.33 - 16.82
Volume9,699,738
Average volume (3 months)17,418,062
Market cap$5.6B
Dividend yield--
Data as of 02/22/2017

Growth & Valuation

Earnings growth (last year)-131.25%
Earnings growth (this year)-46.56%
Earnings growth (next 5 years)+9.40%
Revenue growth (last year)+26.42%
P/E ratioNM
Price/Sales3.32
Price/Book0.95

Competitors

 Today’s
change
Today’s
% change
IONSIonis Pharmaceutical...-0.53-1.15%
MNKMallinckrodt Plc+0.10+0.18%
UTHRUnited Therapeutics ...-20.94-12.47%
ACADACADIA Pharmaceutica...-0.06-0.15%
Data as of 4:00pm ET, 02/22/2017

Financials

Next reporting dateFebruary 28, 2017
EPS forecast (this quarter)$1.22
Annual revenue (last year)$10.4B
Annual profit (last year)-$291.7M
Net profit margin-2.79%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Other
Chairman &
Chief Executive Officer
Joseph C. Papa
Chief Financial Officer &
Executive VP-Finance
Paul S. Herendeen
Corporate headquarters
Laval, Quă©bec

Forecasts


Search for Jobs